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Owing to its safety profile, diagnostic accuracy, and low risk of tumor seeding, endoscopic 
ultrasound–guided fine-needle aspiration (EUS-FNA) represents the preferred modality for 
achieving a tissue confirmation of pancreatic ductal adenocarcinoma (PDAC; J Cancer Res 
Clin Oncol 2012;138: 1433–1441; Gastrointest Endosc 2003;58:690–595; Endoscopy 
2011;43:897–912). In a recent metaanalysis that included 41 studies and 4766 procedures, 
EUS-FNA had a pooled sensitivity of 87% and specificity 96% for the diagnosis of 
malignant pancreatic lesions (Pancreas 2013;42: 20–26). However, the sensitivity of EUS-
FNA is lower in the setting of chronic pancreatitis (CP), where false-negative rates may be 
as high as 40% (Gastrointest Endosc 2005;62: 728–736l; Gastrointest Endosc 2009;70:70–
79). Thus, there is substantial interest in improving the accuracy of cytopathology for 
diagnosing PDAC—and potentially informing long-term prognosis of this deadly cancer—
using novel molecular markers such as microRNAs (miRNAs; Clin Cancer Res 
2011;17:5812–5821). miRNAs are small, noncoding RNAs (17–25 nucleotides long) that 
regulate gene expression post-transcriptionally. These molecules are stable and easily 
recovered from tissue or blood, making EUS-FNA specimens suitable for analysis (Clin 
Chem 2008;54:1716–1724). Unique miRNA “signatures” have been evaluated using 
formalin-fixed, paraffin-embedded specimens, having >90% accuracy in distinguishing 
PDAC from CP and normal pancreata in limited studies (Clin Cancer Res 2011;17:5812–
5821; Clin Chem 2008;54:1716–1724; Int J Cancer 2012;131:E86–95; Expert Rev Mol 
Diagn 2011;11:249–257).
Using samples (n = 95) derived from formalin-fixed, paraffin-embedded tissues of PDAC 
and CP, Brand et al (Clin Gastroenterol Hepatol 2014;12:1717–1723) developed a miRNA 
panel and then analyzed its utility as a diagnostic test using pancreas tissue specimens (n = 
229) derived from EUS-FNA. Starting with 11 candidate miRNAs applied to formalin-fixed, 
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paraffin-embedded specimens (PDAC, n =52; CP, n = 43), the authors identified a panel of 5 
miRNAs (−24, −130b, −135b, −148a, and −196a) having >95% agreement compared with 
standard histopathology when the miRNA classifier score was ≥0.5. Then, the authors 
applied this panel using polymerase chain reaction amplification techniques to EUS-FNA 
specimens prospectively collected at 8 participating centers. Only 1 FNA pass was dedicated 
for miRNA analysis, yet the rate of failed polymerase chain reaction amplification was only 
1 in 229 (0.4%).
Based on standard histopathology, the pretest probability of cancer was 202 in 228 (89%), 
with 184 of 202 cancers being PDAC (excluding non-PDAC cancers, the pre-test probability 
of PDAC was 184 of 202 [88%]). Although the prevalence of concomitant CP is not 
provided—the most common scenario in which the sensitivity of EUS-FNA is diminished—
the sensitivity of cytopathology for detecting PDAC was 79% (145/184). By comparison, 
the miRNA panel correctly diagnosed PDAC in 152 of 184 patients (83%). The combination 
of cytopathology + miRNA resulted in a sensitivity/specificity of 167 of 184 (91%) and 25 
of 26 (96%). Including 1 case of cholangiocarcinoma, the miRNA panel accurately detected 
adenocarcinoma in 130 of the 146 cases detected by cytopathology, with an 11% false-
negative rate. In the setting of negative cytopathology and an miRNA panel score of <0.5, 
the posttest probability of PDAC (the false-negative rate of EUS-FNA cytopathology + 
miRNA) was 17 of 43 (40%).
Because the sensitivity of achieving a diagnosis of PDAC increased from 79% using 
cytopathology alone to 91% when cytopathology was combined with an elevated miRNA 
panel, the authors concluded that a 5-miRNA classifier panel improves the performance 
characteristics of EUS-FNA.
Comment
Although EUS-FNA is safe and accurate, cytopathology may be falsely negative in selected 
cases of PDAC, particularly in the setting of concomitant CP. Strategies to optimize the 
sensitivity of EUS-FNA include performing ≤7 sequential passes and using on-site 
cytopathology (Gastrointest Endosc 2004;59:475–481; Clin Gastroenterol Hepatol 
2012;10:697–703). Enhanced ultrasound imaging, including elastography and the use of 
intravenous contrast agents, may improve the endosonographic visualization of pancreas 
lesions, but have not replaced the need for tissue sampling (Endoscopy 2010;42:564–570; 
Gastrointest Endosc 2012; 76:953–961). Although cytopathology is generally adequate for 
confirming a diagnosis of PDAC, cellular morphology/ grade and tumor staging do not 
adequately inform long-term prognosis in terms of survival and predicted response to 
medical or surgical therapy.
To complement cytopathology, previous studies have explored the incremental yield of 
KRAS staining and fluorescence in situ hybridization analysis using EUS-FNA specimens, 
both of which improve the sensitivity of EUS-FNA (Gastrointest Endosc 2013;78:596–608; 
Gastrointest Endosc 2011;74:541–547; J Gastroenterol Hepatol 2014). However, the 
prevalence of KRAS mutations in the setting of CP lead to false positive results in >10% of 
cases, and the specificity of fluorescence in situ hybridization in this setting is probably 
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<95% (Gastroenterology 1996;110: 227–231; Pancreas 2011;40:1057–1062). Consequently, 
differential miRNA expression in tissue specimens has been explored as a quantitative 
method of augmenting cytopathology for the diagnosis and prognostication of individuals 
with PDAC. A previous study measuring miR-10b expression in EUS-FNA tissue samples 
revealed an association between decreased miR-10b expression in cancer cells with 
improved survival, response to neoadjuvant radiochemotherapy, and delayed time to 
metastasis (Clin Cancer Res 2011;17:5812–5821). Brand and colleagues are the first to 
develop and validate a miRNA panel derived from EUS samples that were prospectively 
collected at multiple centers. The authors’ reported sensitivity of EUS-FNA cytopathology 
(79%) from pancreatic lesions is lower than expected, although we do not know the 
prevalence of concomitant CP, the number of EUS passes sent for cytopathologic review, or 
the use of onsite cytopathology; these factors are associated with a higher diagnostic yield 
from EUS-FNA (Gastrointest Endosc 2004;59:475–481; Am J Gastroenterol 
2011;106:1705–1710). Importantly, the authors only performed 1 dedicated pass for miRNA 
analysis, yet the failure rate for polymerase chain reaction amplification (1/229) was very 
low. However, given the heterogeneity of pancreatic lesions, a second FNA pass would have 
allowed for confirmatory evaluation of the results. Potentially, dedicated passes for miRNA 
profiling would allow for a reduction in needle passes required for cytopathology, which 
could reduce procedure complications and the need for multiple needles, and provide faster 
times to complete EUS-FNA.
The addition of the authors’ miRNA panel identified adenocarcinoma in 130 of 146 cases 
already detected by cytopathology, correctly detected 22 additional cases of PDAC among 
39 samples with negative cytology, and resulted in 1 false-positive result. To minimize the 
likelihood of administering systemic chemotherapy to a patient without cancer, oncologists 
and cytopathologists expect nearly 100% specificity for cancer diagnostics. Similar to 
fluorescence in situ hybridization in the setting of indeterminate bile duct strictures, the 
authors’ miRNA panel may be susceptible to occasional false positivity (Cancer Cytopathol 
2013;121:708–717). In developing this miRNA panel, the pretest probability of PDAC was 
88%; such a high pretest probability minimizes the ramifications of a diagnostic test with 
lower specificity. For example, in a cohort study that includes all patients with CP 
undergoing EUS-FNA, where the pretest probability will be much lower, the number of 
false-positive EUS-FNA samples sent for miRNA analysis will increase. Therefore, 
although further studies are needed to confirm these findings, a positive miRNA panel may 
prompt the clinician to pursue more aggressive follow-up testing, as opposed to proceeding 
directly with cancer treatment.
The utility of miRNA may extend beyond tissue samples. miRNA expression in bodily 
fluids (blood, urine, feces, bile, and pancreatic juice) may enhance or replace carbohydrate 
antigen 19-9 for (1) screening for and diagnosing PDAC in high-risk populations (JAMA 
2014;311:392–404); (2) monitoring or predicting response to systemic therapy (Clin Cancer 
Res 2011;17:5812–5821); and (3) enhancing the diagnostic yield of ERCP-based tissue 
sampling in the setting of concomitant biliary obstruction (Hepatology 2014). The latter 
would be particularly useful in the setting of proximal bile duct strictures, where the 
sensitivity of EUS-FNA is <60% (Gastrointest Endosc 2011;73:71–78).
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As acknowledged by the authors, a combination of negative cytopathology and miRNA 
profiling still resulted in a high (40%) posttest probability of cancer. Clearly, these patients 
cannot be dismissed from cancer surveillance. Currently, clinicians gauge their suspicion of 
pancreatobiliary malignancy on the clinical presentation (including patient age, and “red 
flag” symptoms such as unexplained weight loss and obstructive jaundice), imaging 
presence of an overt mass or duct obstruction, and occasionally serum carbohydrate antigen 
19-9 level, despite its diminished sensitivity and specificity in the setting of bile duct 
obstruction. In our practice, if clinical suspicion is moderate or high, EUS-FNA with 
inconclusive cytopathology typically prompts a second EUS-FNA. In many cases, cancer is 
often confirmed during the second intervention (J Gastroenterol Hepatol 2008;23:567–570; J 
Med Assoc Thai 2012;95 Suppl 2:S68–74), although many of us remain unsettled when the 
cytopathology is incongruent with our clinical suspicion. This may lead to unnecessary 
follow-up testing, improper referral for surgical resection, or a delay in diagnosis. For these 
reasons, miRNA analysis of FNA specimens may inform clinicians to pursue a more or less 
aggressive surveillance program. Brand and colleagues add to a burgeoning field of miRNA-
based cancer diagnostics that is expected to transform and rationalize our approach to 
patients with suspected pancreatobiliary cancer.
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